ClinicalTrials.gg
RecruitingNCT07868939Updated Nov 16, 2026

Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)

A Phase 3 interventional study of VK2735 Oral and Placebo Comparator in Weight Loss, sponsored by Viking Therapeutics, Inc.. Recruiting at 19 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Viking Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Updated Nov 16, 2026Now RecruitingFirst site in United States+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
560
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 998 studies in Weight Loss with a site in United States — 117 open to participants now, 172 under way, 8 of them phase 3. Weight Loss · United States.

Planned enrollment
50th of 915
560 · median 72
Started
2026
with 47 others
Phase 3
32 of 998
3 open now
Primary completion
2028-10
later than 138 of 171 live
Registered
993rd of 998
by date

Among the 998 studies in Weight Loss with a site in United States, this one is the 50th largest by planned enrollment of the 915 interventional ones that give a count, is one of 48 that started in 2026, is one of 32 in phase 3, reaches primary completion later than 138 of the 171 other live ones, and was the 993rd registered.

Weight Loss

1,818 studies on the registry are indexed under Weight Loss; 296 are open to participants now.

Browse Weight Loss studies →

Open to participants now

117 of the 998 studies in Weight Loss with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 117 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 199 Weight Loss studies recruiting now, 73 (37%) set no upper age limit and 109 (55%) stop at 75 or younger; 21 take children under 18; 57 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 998 studies in Weight Loss with a site in United States, or all of them as a file.
02

Study summary

This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.

Read the detailed description

This is a Phase 3, multicenter, 68-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 oral formulation in adults with Type 2 Diabetes Mellitus (T2DM) who are obese or overweight.

03

Conditions studied

  • Weight Loss

Keywords

  • body weight changes
  • body weight
  • weight loss
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years of age at the time of signing the .
  2. (BMI) ≥ 27 kg/m2
  3. Have Type 2 Diabetes Mellitus according to the American Diabetes Association (See Section 12.5), with ≥ 7% to ≤ 11% at screening, on stable therapy for the last 3 months prior to Screening. Participants with HbA1c between 6.5%-6.9% or 11.0%-11.5% are allowed to have a single HbA1c retesting to confirm eligibility. Type 2 Diabetes Mellitus may be treated with diet/exercise alone or any oral glycemic-lowering agent (as per local labeling), EXCEPT for amylin analogues or dipeptidyl peptidase 4 (DPP-4) inhibitors or GLP-1R agonists or dual GLP-1/ glucose-dependent insulinotropic polypeptide (GIP) receptor agonists.

Exclusion criteria

Exclusion Criteria:

  1. History of or current medical disorder that, in the opinion of the Investigator, does not support study participation
  2. Self-reported body weight change of 5% or more within 3 months of screening
  3. Have a prior or planned surgical treatment for obesity such as a gastric sleeve, lap band or any form of bariatric surgery (except for liposuction or abdominoplasty if performed >1 year prior to screening)
  4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as mucosal ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
  5. Have Type 1 Diabetes Mellitus, history of ketoacidosis or hyperosmolar state/coma or any other types of diabetes except Type 2 Diabetes Mellitus (T2DM)
  6. Have had 1 or more episodes of severe hypoglycemia and/or 1 or more episode of hypoglycemia unawareness within 6 months of screening

    • Note: Severe hypoglycemia episodes should be considered when severe cognitive impairment requiring the assistance of another person occurs and the administration of carbohydrate, glucagon, or other resuscitative actions are required. Blood glucose (BG) measurements may not be available during such an event, but neurological recovery attributable to the restoration of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration. If BG measurements are available, the levels associated with severe hypoglycemia are BG \< 54 mg/dL.
  7. Have at least 2 confirmed fasting self-monitoring blood glucose (SMBG) values > 270 mg/dL (on 2 non-consecutive days) within 4 weeks prior to randomization
  8. Have non-proliferative diabetic retinopathy that requires acute treatment OR diabetic macular edema OR proliferative diabetic retinopathy identified during a dilated fundoscopy examination performed within 3 months of screening. Please see Section 7.6.
  9. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
  10. History of acute or chronic pancreatitis
  11. Thyroid disease that is not controlled (Thyroid stimulating hormone (TSH) outside normal range by central lab at screening; one repetition during screening is allowed). Participants with previous history of partial/total thyroidectomy or hypothyroidism may be included, provided their hormone replacement dose has been stable for 3 months prior to screening.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
560 participants (estimated)

Study arms

  • Placebo comparator
    Placebo Assignment

    Placebo comparator orally once daily

    Drug: Placebo Comparator

  • Experimental
    Active Assignment (Dose 1)

    VK2735 Dose level 1 orally once daily

    Drug: VK2735 Oral

  • Experimental
    Active Assignment (Dose 2)

    VK2735 Dose level 2 orally once daily

    Drug: VK2735 Oral

  • Experimental
    Active Assignment (Dose 3)

    VK2735 Dose level 3 orally once daily

    Drug: VK2735 Oral

Interventions

  • VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily

  • DrugPlacebo Comparator

    Placebo comparator administered orally once daily

06

What researchers measure

Primary outcomes

  1. Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily

    To demonstrate that VK2735 daily oral is superior to placebo for percent change in body weight from baseline to week 68

    Time frame: 68 weeks

07

Study locations

19 of 19 sites recruiting
  • Viking Clinical Site #2020
    Tucson, Arizona 85741, United States
    Recruiting
    • · Contact520-333-4515
  • Viking Clinical Site #2015
    Lake Forest, California 92630, United States
    Recruiting
    • · Contact714-550-9990
  • Viking Clinical Site #2059
    Ocoee, Florida 34761, United States
    Recruiting
    • · Contact407-654-2724
  • Viking Clinical Site #2013
    Atlanta, Georgia 30329, United States
    Recruiting
    • · Contact404-920-6201
  • Viking Clinical Site #2001
    Evansville, Indiana 47714, United States
    Recruiting
    • · Contact812-477-2760
  • Viking Clinical Site #2046
    Indianapolis, Indiana 46202, United States
    Recruiting
    • · Contact504-336-2667
  • Viking Clinical Site #2009
    Valparaiso, Indiana 46383, United States
    Recruiting
    • · Contact219-464-8302
  • Viking Clinical Site #2004
    Richfield, Minnesota 55423, United States
    Recruiting
    • · Contact952-922-7000
  • Viking Clinical Site #2029
    Jackson, Mississippi 39206, United States
    Recruiting
    • · Contact770-330-4157
  • Viking Clinical Site #2028
    Springfield, Missouri 65807, United States
    Recruiting
    • · Contact504-338-0917
  • Viking Clinical Site #2052
    Albuquerque, New Mexico 87107, United States
    Recruiting
    • · Contact505-243-1627
  • Viking Clinical Site #2039
    Binghamton, New York 13905, United States
    Recruiting
    • · Contact607-800-5777
  • Viking Clinical Site #2023
    Medford, Oregon 97504, United States
    Recruiting
    • · Contact541-858-1018
  • Viking Clinical Site #2002
    East Greenwich, Rhode Island 02818, United States
    Recruiting
    • · Contact401-739-9350
  • Viking Clinical Site #2044
    Charleston, South Carolina 29407, United States
    Recruiting
    • · Contact843-432-2477
  • Viking Clinical Site #2030
    Hendersonville, Tennessee 37075, United States
    Recruiting
    • · Contact504-339-0917
  • Viking Clinical Site #2031
    Abilene, Texas 79606, United States
    Recruiting
    • · Contact325-400-1150
  • Viking Clinical Site #2011
    Seattle, Washington 98105, United States
    Recruiting
    • · Contact206-536-3030
  • Viking Clinical Site #2042
    Spokane, Washington 99218, United States
    Recruiting
    • · Contact509-505-6227
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2028, 23 months later.

Of 23 phase 3 interventional studies under Weight Loss, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 28. This study's planned 23 months is close to that.

Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Oct 16, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2026
First posted
Oct 9, 2026
StartEst.
Nov 2026was Oct 2026
Primary completionEst.
Oct 2028
CompletionEst.
Dec 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 16, 2026
Sites
19 sites added — first site in United States
Show 19 added (19 United States)
  • Viking Clinical Site #2020 · Tucson, United States
  • Viking Clinical Site #2015 · Lake Forest, United States
  • Viking Clinical Site #2059 · Ocoee, United States
  • Viking Clinical Site #2013 · Atlanta, United States
  • Viking Clinical Site #2001 · Evansville, United States
  • Viking Clinical Site #2046 · Indianapolis, United States
  • Viking Clinical Site #2009 · Valparaiso, United States
  • Viking Clinical Site #2004 · Richfield, United States
  • Viking Clinical Site #2029 · Jackson, United States
  • Viking Clinical Site #2028 · Springfield, United States
  • Viking Clinical Site #2052 · Albuquerque, United States
  • Viking Clinical Site #2039 · Binghamton, United States
  • Viking Clinical Site #2023 · Medford, United States
  • Viking Clinical Site #2002 · East Greenwich, United States
  • Viking Clinical Site #2044 · Charleston, United States
  • Viking Clinical Site #2030 · Hendersonville, United States
  • Viking Clinical Site #2031 · Abilene, United States
  • Viking Clinical Site #2011 · Seattle, United States
  • Viking Clinical Site #2042 · Spokane, United States
Nov 16, 2026
Start date
Oct 16, 2026→Nov 2026
Oct 16, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPercent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily: how it is measured was reworded
Oct 16, 2026
Registered
First appeared on the registry
Oct 9, 2026
Show all 3 updates
  1. Nov 16, 2026
    Not yet recruiting→Recruiting
    19 sites added — first site in United States
    Show 19 added (19 United States)
    • Viking Clinical Site #2020 · Tucson, United States
    • Viking Clinical Site #2015 · Lake Forest, United States
    • Viking Clinical Site #2059 · Ocoee, United States
    • Viking Clinical Site #2013 · Atlanta, United States
    • Viking Clinical Site #2001 · Evansville, United States
    • Viking Clinical Site #2046 · Indianapolis, United States
    • Viking Clinical Site #2009 · Valparaiso, United States
    • Viking Clinical Site #2004 · Richfield, United States
    • Viking Clinical Site #2029 · Jackson, United States
    • Viking Clinical Site #2028 · Springfield, United States
    • Viking Clinical Site #2052 · Albuquerque, United States
    • Viking Clinical Site #2039 · Binghamton, United States
    • Viking Clinical Site #2023 · Medford, United States
    • Viking Clinical Site #2002 · East Greenwich, United States
    • Viking Clinical Site #2044 · Charleston, United States
    • Viking Clinical Site #2030 · Hendersonville, United States
    • Viking Clinical Site #2031 · Abilene, United States
    • Viking Clinical Site #2011 · Seattle, United States
    • Viking Clinical Site #2042 · Spokane, United States
    + 1 other change: verification date
  2. Oct 16, 2026
    Start date Oct 16, 2026→Nov 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPercent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once daily: how it is measured was reworded
    + 2 other changes: description and arm descriptions
  3. Oct 9, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07868939
Responsible party
Sponsor
First posted
Oct 9, 2026
Start date
Nov 2026 (estimated)
Primary completion
Oct 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Hubert Chen, MD
Contact
clinicaltrials@vikingtherapeutics.com
8587044660

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VK2735

Start the discussion